The site will be unavailable in 47 minutes for scheduled maintenance.

Use access key #2 to skip to page content.
$4.51 -0.14 (-3.01%)
11/21/2008 4:00 PM

Dendreon Corp (DNDN)

CAPS Rating:
**

A biotechnology company focused on the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating DNDN

Add Stock to Watchlist

What the Community Thinks

Total Members

876 Outperforms
223 Underperforms
 

All-Stars

125 Outperforms
60 Underperforms
 

Wall Street

1 Outperforms
6 Underperforms
 

Members bullish on DNDN are also bullish on:

Members bearish on DNDN are also bearish on:

Ticker Tags

Rule Breakers Universe (137), Micro Cap (5043), Biotechnology (230)
Suggest a tag

Dendreon Corp At A Glance

Current Price: $4.51
Last Trade Time: 11/21/2008 4:00 PM
Open: $4.71
Previous Close: $4.65
Daily Range: $4.34 - $4.74
52-Week Range: $4.05 - $10.00
Volume: 4,186,266
Market Cap: $450.78M
P/E Ratio: 0.00
Compare Our Special Broker Offers!

Stock Trends

DNDN VS S&P 500 (SPY)

News & Discussion Boards

Other News Headlines for DNDN

More Headlines...

Top Bull Pitch

Recs

1

Dendreon Corp (DNDN)

Avatar Crosh (38.85) Submitted: 11/05/08 11:44 AM

Risk/Reward ratio people. If anyone reading this review has ever been to a casino, imagine yourself standing at a roulette table and putting 400 dollars down on black. You have about a 50/50 chance - you either double your money or lose it. In the case of Dendreon, even pessimistic analysts give ...More

Replies: 0 | Reply | Permalink

Top Bear Pitch

Recs

3

Dendreon Corp (DNDN)

Avatar TheGarcipian (99.51) Submitted: 6/13/08 1:30 PM

Doubling-down on this one. Still lots of cash going out this company's doors, and in the economy, things are going to get a lot tighter than looser. This company still enjoys (some) overblown hype on its cancer drug, as shown by the FDA's calls, but I don't think that's going to last much longer. It...More

Replies: 3 | Reply | Permalink

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 264 :   1 2 3 4 5 Next » Jump to page:

Recs

0

 (DNDN)

Avatar jeffduby (96.89) Submitted: 11/19/08 12:50 PM : Underperform Start Price: $4.82 DNDN Score: -2.93

This stock is hemmoraging cash. Also has terrible management performance. Chart scary as hell

Report this Post Replies: 0 | Reply | Permalink

Recs

1

 (DNDN)

Avatar Crosh (38.85) Submitted: 11/05/08 11:44 AM : Outperform Start Price: $5.15 DNDN Score: 10.60

Risk/Reward ratio people. If anyone reading this review has ever been to a casino, imagine yourself standing at a roulette table and putting 400 dollars down on black. You have about a 50/50 chance - you either double your money or lose it. In the case of Dendreon, even pessimistic analysts give PROVENGE about a 50/50 chance of gaining approval. Now imagine that instead of doubling your 400 dollar investment or losing it you have equal odds to multiply that amount by 15 (a realistic estimate for the new price of DNDN if PROVENGE is approved) or halve it (and DNDN simply tries again or is bought out). If you have some extra money to risk DNDN is a matter of playing your odds.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (DNDN)

Avatar knucklebuster123 (< 20) Submitted: 10/31/08 4:16 PM : Outperform Start Price: $4.90 DNDN Score: 13.76

Provenge WILL receive FDA approval in '09.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (DNDN)

Avatar big63bo (< 20) Submitted: 10/31/08 3:15 PM : Outperform Start Price: $4.88 DNDN Score: 14.45

I belived the stock or drug will be apporved, provenge

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (DNDN)

Avatar benthehen95 (35.39) Submitted: 10/30/08 5:52 PM : Outperform Start Price: $4.81 DNDN Score: 14.09

provenge likely approval, risk reward is very favorable at 5

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 264 :   1 2 3 4 5 Next » Jump to page:

Wall Street

Results 1 - 7 of 7  

picks per page. CHANGE

Top
Pick
Member NameMember RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackMerrimanCo < 20 10/16/08 Underperform NS $4.95-8.89%-17.16%-8.27
TrackJMP < 20 07/12/07 Underperform NS $7.88-42.77%-50.23%-7.46
TrackBreanMurray 61.07 05/11/07 Underperform NS $5.13-12.09%-49.36%-37.27
TrackBofASec 95.85 05/10/07 Underperform NS $5.75-21.57%-49.69%-28.12
TrackUBS 85.75 05/08/07 Underperform NS $17.14-73.69%-49.63%+24.06
TrackJimCramer 85.65 05/07/07 Underperform 3W $17.92-74.83%-49.76%+25.07
TrackNextGen 33.67 05/03/07 Outperform NS $18.13-75.12%-49.45%-25.68

Results 1 - 7 of 7  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners

Sponsored Links